PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: June 25, 2008

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/519,890
Filing Date	7/11/2003
First Named Inventor	Briony FORBES
Art Unit	1649
Examiner Name	Christina M. Borgeest
Attorney Docket Number	029860-0190

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number-Kind Code[2] (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
/CB/	A1	CLEMMONS, David R.; "Use of mutagenesis to probe IGF-binding protein structure/function relationships"; Endocrine Reviews (2001), vol. 22 (6); pp. 800-817	
/CB/	A2	QIN XUEZHONG et al.; "Studies on the role of human insulin-like growth factor-II (IGF-II)-dependent IGF binding protein (hIGFBP)-4 protease in human osteoblasts using protease-resistant IGBP-4 analogs"; Journal of Bone and Mineral Research (1999), vol. 14(12), pp. 2079-2088	
/CB/	A3	MIYAKOSHI, Naohisa et al.; "Systemic administration of insulin-like growth factor (IGF)-binding proteln-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism; Endocrinology (2001); vol. 142(6); pp. 2641-2648	
/CB/	A4	CANOVER, C. A. et al.; "Cleavage analysis of insulin-like growth-factor (IGF) dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants; Journal of Biological Chemistry, American Society of Biolochemical Biologist, Birmingham, US (1995); vol., 270 (9), pp. 4395-4400	
/CB/	A5	CLEMMONS, D. et al.; "Role of insulin-like growth factor binding protein in the control of IGF actions"; Progress of Growth Factor Research"; vol. 6, no. 2-4; 1995; pp. 357-366	
/CB/	A6	BRAMANI, S. et al.; "Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I"; Journal of Molecular Endocrinology"; vol. 23, 1999, pp. 117-123	

Examiner Signature	/Christina Borgeest/ (09/26/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CB/